Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return
Executive Summary
Pfizer will have to show a "unique" benefit associated with Bextra in order to justify a return to the U.S. market, FDA Office of New Drugs Director John Jenkins said during an April 7 media conference call announcing the withdrawal of the COX-2 inhibitor
You may also be interested in...
Pfizer Sales Manager Sentenced for Bextra Off-Label Promotion
Department of Justice sentences former regional manager to pay $75,000 fine and probation; she is second Pfizer sales manager to face indictment.
Bextra Settlement Coming Soon: Industry Should Brace For Impact
Pfizer's pending $2.3 billion settlement of an investigation into the promotion of Bextra (valdecoxib) sets a new record for a pharma company's liability in a health care fraud case, and begs the question of how big the political liability facing the industry will be as the latest wave of marketing cases reaches settlement
Bextra Settlement Coming Soon: Industry Should Brace For Impact
Pfizer's pending $2.3 billion settlement of an investigation into the promotion of Bextra (valdecoxib) sets a new record for a pharma company's liability in a health care fraud case, and begs the question of how big the political liability facing the industry will be as the latest wave of marketing cases reaches settlement